New hepatitis b pill shows promise in early human trial
NCT ID NCT04536337
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests an experimental oral drug called ALG-000184 in healthy volunteers and people with chronic hepatitis B. The main goals are to check safety, how the body processes the drug, and whether it can lower hepatitis B virus levels. Participants take the drug daily for up to 12 weeks, sometimes combined with a standard treatment. Results will help decide if larger studies are warranted.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ALG-000184 (an experimental oral drug)
What this could lead to
If successful, this could point toward a new treatment option for chronic hepatitis B, potentially reducing virus levels and improving disease control.
What could go wrong
This is an early Phase 1 trial focused on safety, so it's too soon to know if ALG-000184 will work. The drug may cause side effects or fail to reduce the virus effectively.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
ACS
Auckland, New Zealand
-
CAP Research
Quatre Bornes, Mauritius, 72218, Mauritius
-
Nanfang Hospital of Southern Medical University
Guangzhou, Guangdong, China
-
PMSI Republican Clinical Hospital "T. Mosneaga", ARENSIA Exploratory Medicine Phase I Unit
Chisinau, Moldova
-
Prince of Wales
Shatin, Hong Kong
-
Queen Mary Hospital
Hong Kong, Hong Kong
-
Saint Vincent's Hospital Melbourne
Fitzroy, Victoria, 3065, Australia
-
The First Hospital of Jilin University
Changchun, Jilin, 130021, China
-
The Second Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, 400016, China
-
Western Health
Footscray, Victoria, 3011, Australia